Receptos to be Added to Russell 3000(R) Index on June 28, 2013
June 26 2013 - 8:00AM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced that it is set to join the
Russell 3000® Index when Russell Investments reconstitutes its
comprehensive set of U.S. and global equity indexes on June 28,
2013.
Annual reconstitution of Russell's U.S. indexes captures the
4,000 largest U.S. stocks as of the end of May, ranking them by
total market capitalization. Membership in the Russell 3000, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell 2000® Index as
well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by
objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. Approximately $4.1
trillion in assets are benchmarked to the Russell Indexes. Russell
calculates more than 700,000 benchmarks daily covering
approximately 98% of the investable market globally, more than 80
countries and 10,000 securities. These investment tools originated
from Russell's multi-manager investment business in the early 1980s
when the company saw the need for a more objective, market-driven
set of benchmarks in order to evaluate outside investment
managers.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is a sphingosine 1-phosphate 1
(S1P1) receptor small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis and
inflammatory bowel disease. The Company is also developing RPC4046,
an anti-interleukin-13 antibody for an allergic/immune-mediated
orphan disease, eosinophilic esophagitis. Receptos has established
expertise in high resolution protein crystal structure
determination, biology and drug discovery for G-protein-coupled
receptors.
Forward-looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements do not constitute guarantees of
future performance and are subject to a number of risks that could
cause actual results to differ materially from those anticipated.
Information on various risks that could affect the Company are
detailed in the Company's filings with the Securities and Exchange
Commission, including the Company's Quarterly Report on Form 10-Q
for the quarter ended March 31, 2013.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Jul 2024 to Aug 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Aug 2023 to Aug 2024